News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Johnson & Johnson: In Talks To Resolve US Probe Of Risperdal Marketing
November 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- Johnson & Johnson (JNJ) said it's in discussions with the government to resolve a long-running investigation of whether it improperly marketed the antipsychotic Risperdal.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Rare diseases
FDA Overruled Reviewers in Approving Stealth’s Barth Syndrome Treatment
November 5, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Novo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid
November 4, 2025
·
1 min read
·
Annalee Armstrong
FDA
UPDATE: Tidmarsh Waffles on Resignation, Will Fight To Clear Name
November 3, 2025
·
3 min read
·
Tristan Manalac
IN PARTNERSHIP WITH ELEMENT
Pharma Faces Investor Woes and Tariff Threats, Turns to AI and Collaboration for Survival
November 3, 2025
·
5 min read
·
BioSpace Insights
